PARTI . Overview Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Our approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Our re...
Q2 FY2026 — expected 2026-09-19
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | ACXP | discussed_in_filing Artificial Intelligence | |
| topic_mention | ACXP | discussed_in_filing Cybersecurity | |
| topic_mention | ACXP | discussed_in_filing Trusted Computing | |
| topic_mention | ACXP | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ACXP | discussed_in_filing Regulation | |
| topic_mention | ACXP | discussed_in_filing Healthcare & Bio | |
| topic_mention | ACXP | discussed_in_filing Artificial Intelligence | |
| topic_mention | ACXP | discussed_in_filing Cybersecurity | |
| topic_mention | ACXP | discussed_in_filing Trusted Computing | |
| topic_mention | ACXP | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ACXP | discussed_in_filing Regulation | |
| topic_mention | ACXP | discussed_in_filing Healthcare & Bio | |
| topic_mention | ACXP | discussed_in_filing Artificial Intelligence | |
| topic_mention | ACXP | discussed_in_filing Cybersecurity | |
| topic_mention | ACXP | discussed_in_filing Trusted Computing | |
| topic_mention | ACXP | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ACXP | discussed_in_filing Regulation | |
| topic_mention | ACXP | discussed_in_filing Healthcare & Bio | |
| topic_mention | ACXP | discussed_in_filing Artificial Intelligence | |
| topic_mention | ACXP | discussed_in_filing Cybersecurity |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001104659-26-027052 | EDGAR | 82K words |
| 2025-03-17 | 2024-12-31 | 0001558370-25-003117 | EDGAR | — |
| 2024-03-15 | 2023-12-31 | 0001558370-24-003401 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0001558370-23-003929 | EDGAR | — |
| 2022-03-16 | 2021-12-31 | 0001410578-22-000399 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-109698 | EDGAR | 46K words |
| 2025-08-11 | 2025-06-30 | 0001558370-25-011045 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007371 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001558370-24-015310 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011587 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008130 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018824 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001558370-23-014645 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001558370-23-009495 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017408 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001410578-22-002396 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001410578-22-001250 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-09 | 0001104659-26-025003 | EDGAR | 1K words |
| 2025-09-22 | 0001104659-25-092166 | EDGAR | — |
| 2025-09-19 | 0001104659-25-091733 | EDGAR | — |
| 2025-07-31 | 0001104659-25-072529 | EDGAR | — |
| 2025-07-17 | 0001104659-25-068659 | EDGAR | — |
| 2025-06-20 | 0001104659-25-060902 | EDGAR | — |
| 2025-05-13 | 0001104659-25-047566 | EDGAR | — |
| 2025-05-08 | 0001104659-25-046167 | EDGAR | — |
| 2025-03-28 | 0001104659-25-029370 | EDGAR | — |
| 2025-03-18 | 0001104659-25-024731 | EDGAR | — |
79 total filings indexed. 52 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001736243 |
| Ticker | ACXP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report